Immune Design Corp. is a clinical-stage immunotherapy company, which focuses on cancer with next-generation in vivo approaches designed to enable the body&#x27;s immune system to fight disease. It includes products candidates from discovery platforms, IMDZVe or ZVex, and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Seattle, WA.
